This approval represents a meaningful shift in obesity treatment, expanding options beyond injectable therapies and introducing a more convenient, patient-centric approach that may support earlier intervention and long-term adherence
Blog last updated: October 15, 2025
Early research suggests retatrutide may produce greater weight loss in some cases, but long-term comparative studies are still ongoing
The GLP-1 boom is a case study in modern healthcare capitalism, a reminder that innovation and exploitation can coexist in the same infrastructure
If you need to shift your injection day, Eli Lilly recommends that the interval between any two doses should be at least 72 hours (3 days)
The 9 exercises are chosen to be accessible regardless of experience level, and most require only a single dumbbell or kettlebell